Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEA-BCMA
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SEA-BCMA is a humanized, non-fucosylated IgG1 monoclonal antibody that targets B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma. The drug is designed to enhance immune-mediated killing of BCMA-expressing cells by increasing FcγRIII binding and promoting both antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. It also blocks BCMA-mediated pro-survival and proliferative signaling pathways in tumor cells. SEA-BCMA has demonstrated activity in preclinical models and early-phase clinical trials for relapsed/refractory multiple myeloma, including patients previously treated with other classes of anti-myeloma agents. The drug was originally developed by Seattle Genetics (now Seagen), which has since been acquired by Pfizer[2][4][5][6].
- Other names
- Anti-bcma antibody sea-bcmaNonfucosylated humanized immunoglobulin G1 monoclonal antibody targeting B-cell maturation antigen
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on SEA-BCMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEA-BCMA.